These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Costs and Cost Drivers of Providing Option B+ Services to Mother-Baby Pairs for PMTCT of HIV in Health Centre IV Facilities in Jinja District, Uganda. Mukose AD, Kebede S, Muhumuza C, Makumbi F, Komakech H, Bayiga E, Busobozi D, Musinguzi J, Kuznik A, Stegman P, Forsythe S, Kagaayi J. Biomed Res Int; 2020 Aug 01; 2020():2875864. PubMed ID: 32550228 [Abstract] [Full Text] [Related]
30. Protocol for the evaluation of the population-level impact of Zimbabwe's prevention of mother-to-child HIV transmission program option B+: a community based serial cross-sectional study. Koyuncu A, Dufour MK, McCoy SI, Bautista-Arredondo S, Buzdugan R, Watadzaushe C, Dirawo J, Mushavi A, Mahomva A, Cowan F, Padian N. BMC Pregnancy Childbirth; 2019 Jan 08; 19(1):15. PubMed ID: 30621615 [Abstract] [Full Text] [Related]
31. Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. Ciaranello AL, Perez F, Engelsmann B, Walensky RP, Mushavi A, Rusibamayila A, Keatinge J, Park JE, Maruva M, Cerda R, Wood R, Dabis F, Freedberg KA. Clin Infect Dis; 2013 Feb 08; 56(3):430-46. PubMed ID: 23204035 [Abstract] [Full Text] [Related]
33. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, Rouet F, Becquet R, Leroy V, El-Sadr WM, Abrams EJ, Dabis F. PLoS Med; 2007 Aug 08; 4(8):e257. PubMed ID: 17713983 [Abstract] [Full Text] [Related]
34. Efavirenz-based antiretroviral therapy versus nevirapine-including regimens for prevention of mother-to-child transmission of HIV option B plus in resource-limited settings: is there anything missing? De Nardo P, Gentilotti E, Nguhuni B, Vairo F, Chaula Z, Nicastri E, Ippolito G. Expert Rev Anti Infect Ther; 2016 Aug 08; 14(1):19-27. PubMed ID: 26559430 [Abstract] [Full Text] [Related]
35. Cost-effectiveness of new WHO recommendations for prevention of mother-to-child transmission of HIV in a resource-limited setting. Shah M, Johns B, Abimiku A, Walker DG. AIDS; 2011 May 15; 25(8):1093-102. PubMed ID: 21505317 [Abstract] [Full Text] [Related]
37. Acceptability of lifelong treatment among HIV-positive pregnant and breastfeeding women (Option B+) in selected health facilities in Zimbabwe: a qualitative study. Chadambuka A, Katirayi L, Muchedzi A, Tumbare E, Musarandega R, Mahomva AI, Woelk G. BMC Public Health; 2017 Jul 25; 18(1):57. PubMed ID: 28743251 [Abstract] [Full Text] [Related]
38. Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries. Sweat MD, O'Reilly KR, Schmid GP, Denison J, de Zoysa I. AIDS; 2004 Aug 20; 18(12):1661-71. PubMed ID: 15280777 [Abstract] [Full Text] [Related]
39. Prevention of mother-to-child transmission of HIV: cost-effectiveness of antiretroviral regimens and feeding options in Rwanda. Binagwaho A, Pegurri E, Drobac PC, Mugwaneza P, Stulac SN, Wagner CM, Karema C, Tsague L. PLoS One; 2013 Aug 20; 8(2):e54180. PubMed ID: 23437040 [Abstract] [Full Text] [Related]